Mattek Corporation — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): The perioral route for drug administration remains th

Description

DESCRIPTION (provided by applicant): The perioral route for drug administration remains the most convenient way of clinical therapy and is preferred by patients, however, good bioavailability is a necessary characteristic of new candidate therapeutics. A key parameter for determining oral bioavailability is drug transport and permeability across the small intestine (SI) epithelium. Therefore, in vitro models of SI epithelium that accurately predict in vivo human transport/permeability of candidate drugs are of high interest to the pharmaceutical industry. Currently available in vitro models have significant deficiencies which limit their utility for dru development applications, including poor correlation to in vivo human carrier-mediated transport and parcellular permeation, as well as a lack of in vivo human small intestine metabolic enzyme activity. The current proposal aims to develop an in vitro human SI for use in pharmaceutical development applications. The SI model will consist of primary huma